Loss of Yasmin contraceptive patent knocks Bayer

FRANKFURT (Reuters) - Shares in Bayer slumped as much as 5.6 percent on Tuesday after a U.S. court voided the patent on its Yasmin oral contraceptive drug, prompting the German group to tweak its healthcare margin goal. 8 months ago